Scedosporium species can be virtually indistinguishable from Aspergillus species; however, management presents unique challenges.
Like Aspergillus species, S. apiospermum causes a wide spectrum of pulmonary disease ranging from allergic bronchopulmonary mycosis to uncomplicated fungal balls to more extensive cavitary disease with or without angioinvasion [1] . Within this disease spectrum, our patient presented with a semi-invasive chronic necrotizing pulmonary infection akin to CNPA. Typical presenting symptoms include chronic cough and intermittent hemoptysis. Systemic symptoms, such as fever and weight loss, are less common. Risk factors include moderate immunosuppression, such as that caused by diabetes mellitus or corticosteroid use [2] [3] [4] [5] . This is in contrast to patients with invasive pulmonary mycoses and/or disseminated disease who are profoundly immunosuppressed as a result of solid-organ transplant, bone marrow transplant, or AIDS [6] [7] [8] . Previous lung damage with underlying cavitary disease is extremely common. In the largest series to date of patients with CNPA, more than 90% of patients had a prior history of mycobacterial disease [5] . In this series, the most common imaging (Figure 1 ). Other, less frequent findings of CNPA have included bronchopleural fistula (19%) and emphysema (14%), which were not seen in our patient [5] .
Because of the similar clinical and radiographic findings of Scedosporium and Aspergillus species, microbiologic characterization is critical to make the diagnosis. S. apiospermum grows rapidly on standard mycologic media, such as Sabouraud glucose agar, at 25°C. Macroscopically, colonies are initially white and turn gray over time. Microscopic examination reveals irregularly branching septate hyphae with a single oval conidium with truncate bases forming on conidiophores (Figure 2 , arrows). This appearance can be easily distinguished from that of the aggregate conidia of Aspergillus species, which project in columns or chains from a unique flask-shaped vesicle at the end of a long conidiophore.
Chronic necrotizing pulmonary scedosporiosis presents unique management challenges. In vitro resistance to and clinical failure of amphotericin therapy have been commonly reported with scedosporiosis. Broad-spectrum azoles, such as voriconazole and posaconazole, as well as caspofungin, show superior in vitro activity [9] . Recent reports of consistent clinical success with voriconazole have made this the antifungal drug of choice [10] . Duration of treatment is not yet well defined.
Our patient was not a candidate for surgical resection because of poor pulmonary functional capacity and the extensive nature of her lesions. For management of her hemoptysis, selective embolization of 4 right bronchial arteries was performed. She began voriconazole therapy and has significantly improved, having not had progression of her hemoptysis or required hospitalization during the past 6 months. 
